Juvenescence

MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments using clinical biomarkers.

Portage Pharmaceuticals LTD. is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression, restore protein function, and improve medical outcomes. The Company has spun out its lead asset, PPL-003, to ophthalmic indications and has licensed this CellPorter technology to EyGen, a new ophthalmic company.

LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.

LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.

Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.

BHB Therapeutics is developing novel approaches to induce a state of ketosis, which may have protective effects against age-related disease.

AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. The company utilizes its proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create potential treatments for age-related conditions. Its primary candidates in development include AGEX-BAT1, a cell therapy targeting metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug formulation intended to enhance regenerative capabilities in aged tissues. The company also offers human embryonic stem cells and tools for genomic interpretation through its GeneCards Database Suite. AgeX collaborates with research institutions, including the University of California, Irvine, on projects related to neurological disorders. Founded in 2017 and based in Alameda, California, AgeX aims to tackle significant challenges in the field of aging and regenerative medicine.

Napa Therapeutics is a biotechnology company focused on a novel target linked to one of the fundamental processes of aging. A privately held British Virgin Islands company with an office in the Isle of Man, Napa is developing small molecule drugs to address this target.

FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. The company utilizes its proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create potential treatments for age-related conditions. Its primary candidates in development include AGEX-BAT1, a cell therapy targeting metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug formulation intended to enhance regenerative capabilities in aged tissues. The company also offers human embryonic stem cells and tools for genomic interpretation through its GeneCards Database Suite. AgeX collaborates with research institutions, including the University of California, Irvine, on projects related to neurological disorders. Founded in 2017 and based in Alameda, California, AgeX aims to tackle significant challenges in the field of aging and regenerative medicine.

LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.